Antares Pharma Inc

Antares Pharma — H.C. Wainwright 20th Annual Global Investment Conference (September 2018)

26 slides from Antares Pharma's conference presentation, Sep 6, 2018

  1. Slide 1: H.C. Wainwright 20th Annual Global Investment Conference

    Slide 1: H.C. Wainwright 20th Annual Global Investment Conference

    NASDAQ: ATRS H.C. Wainwright 20th Annual Global Investment Conference September 6, 2018 Robert F. Apple President and Chief Executive Officer Exhibit 99.1

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ mate

  3. Slide 3: Antares Pharma: A Growing Specialty Pharmaceutical Company

    Slide 3: Antares Pharma: A Growing Specialty Pharmaceutical Company

    Antares Pharma A Growing Specialty Pharmaceutical Company With 2017 Revenue of $54.5 Million – 2018 year-to-date revenue through June 30 of $26.9 Million An Innovative Leader in Self-Administered Injection Technology Novel Drug Delivery Technology Can Provide Numerous Product Opportunities and Life

  4. Slide 4: Antares Pharma – 2018 Significant Achievements

    Slide 4: Antares Pharma – 2018 Significant Achievements

    Antares Pharma – 2018 Significant Achievements February approval of Makena® Auto Injector utilizing QuickShot® Device August approval of a Therapeutically Equivalent Generic to the EpiPen® August Alliance Business Transaction Announced – Pfizer Rescue Pen Pending XYOSTED™ NDA – PDUFA Date September

  5. Slide 5: Antares Pharma

    Slide 5: Antares Pharma

    Antares Pharma Two combination products approved and on the U.S. market (OTREXUP®, Sumatriptan) AMAG’s Makena® subcutaneous auto injector launched in the U.S. in March 2018 Teva’s epinephrine injection USP approved utilizing our VIBEX® auto injector – therapeutically equivalent to branded EpiPen® XY

  6. Slide 6: Proprietary and Partnered Commercial Products

    Slide 6: Proprietary and Partnered Commercial Products

    NASDAQ: ATRS Proprietary and Partnered Commercial Products

  7. Slide 7: OTREXUP (methotrexate) injection for subcutaneous use

    Slide 7: OTREXUP (methotrexate) injection for subcutaneous use

    OTREXUP® (methotrexate) injection for subcutaneous use 8,629 9,262 10,198 11,051 9,475 10,004 11,286 10,793 Indicated for use in adults with RA, children with pJIA and adults with psoriasis 2017 Revenue $17.9M – 2018 YTD Revenue $7.7M

  8. Slide 8: VIBEX Sumatriptan Injection USP

    Slide 8: VIBEX Sumatriptan Injection USP

    VIBEX® Sumatriptan Injection USP Total prescriptions for Q218 increased 11.3% versus the same period last year – 2018 YTD Revenue $5.5M VIBEX® Sumatriptan Injection USP for acute treatment of migraine and cluster headaches in adults – distributed by Teva *Symphony Health Solutions Quarterly TRx Data

  9. Slide 9: Makena Subcutaneous Auto Injector – FDA Approved

    Slide 9: Makena Subcutaneous Auto Injector – FDA Approved

    Makena® Subcutaneous Auto Injector– FDA Approved AMAG/Makena® collaboration began in 2014 - Alliance terms: Cost plus product transfer price (fully packaged QuickShot® device), plus royalty on net sales and sales performance milestones QuickShot® device used to develop a once-weekly subcutaneous inj

  10. Slide 10: Makena hydroxyprogesterone caproate injection

    Slide 10: Makena hydroxyprogesterone caproate injection

    Makena® hydroxyprogesterone caproate injection Subcutaneous injection Intramuscular injection Efficient Discreet Administration friendly ü ü ü Makena® - Used to Reduce the Risk of Preterm Birth in Certain At-Risk Women

  11. Slide 11: Epinephrine Injection USP Approved

    Slide 11: Epinephrine Injection USP Approved

    Epinephrine Injection USP Approved!! Epinephrine Injection USP approved August 16, 2018 Therapeutically Equivalent and Fully Substitutable at the pharmacy Antares receives an undisclosed milestone payment from Teva for approval Pre-launch devices have been shipped to Teva – additional purchase order

  12. Slide 12: Proprietary and Partnered Pipeline Products

    Slide 12: Proprietary and Partnered Pipeline Products

    NASDAQ: ATRS Proprietary and Partnered Pipeline Products

  13. Slide 13: XYOSTED – Subcutaneous Testosterone Enanthate in an auto injector

    Slide 13: XYOSTED – Subcutaneous Testosterone Enanthate in an auto injector

    Name XYOSTED™ - Subcutaneous Testosterone Enanthate in an auto injector Dosing Once weekly, single use, fixed dose subcutaneous product Doses 50 mg/0.5 mL TE in solution 75 mg/0.5 mL TE in solution 100 mg/0.5 mL TE in solution Product Features Easy to use and store at room temperature Auto injector

  14. Slide 14: XYOSTED Regulatory Update

    Slide 14: XYOSTED Regulatory Update

    XYOSTED™ Regulatory Update Received a Complete Response Letter from the FDA on October 20, 2017 The FDA cited two deficiencies: Clinically meaningful increase in blood pressure Concern regarding the occurrence of depression/suicidality Complete response resubmitted and accepted as a complete, class

  15. Slide 15: Testosterone Replacement Market

    Slide 15: Testosterone Replacement Market

    Testosterone Replacement Market: Jan 2015 – July 2018 Retail Prescriptions Symphony Health Solutions: Phast IDV – Total 2017 TRx’s 6.5M 2016 2015 2018 15

  16. Slide 16: XYOSTED Commercial Launch Planning Underway

    Slide 16: XYOSTED Commercial Launch Planning Underway

    XYOSTED™ Commercial Launch Planning Underway PDUFA Date: September 29, 2018 Key Next Steps: Recruitment of ~60 sales representatives and on-boarding (pending FDA approval) Finalization of WAC price Finalization of Payer Access Strategy and Prioritization Finalization of all Marketing Assets and Acti

  17. Slide 17: Alliance Business Update

    Slide 17: Alliance Business Update

    Alliance Business Update Exenatide Teriparatide Teva filed against Byetta® (exenatide) and they are working through the regulatory approval process using the ANDA pathway. ATRS believes Teva has first to file status and 180 days of marketing exclusivity, launch pending approval Teva filed against Fo

  18. Slide 18: Second Quarter & Year-To-Date Financial Results and Progress Against 2018 Goals

    Slide 18: Second Quarter & Year-To-Date Financial Results and Progress Against 2018 Goals

    NASDAQ: ATRS Second Quarter & Year-To-Date Financial Results and Progress Against 2018 Goals

  19. Slide 19: Second Quarter and Year-to-Date 2018 Financial Results

    Slide 19: Second Quarter and Year-to-Date 2018 Financial Results

    Second Quarter and Year-to-Date 2018 Financial Results Three Months Ended June 30 Increase Six Months Ended June 30 Increase 2018 2017 (Decrease) 2018 2017 (Decrease) Product Revenue $ 11,095 $ 7,344 51% $ 22,044 $ 17,381 27% Licensing/Development/Royalty Revenue 3,067 6,072 (49%) 4,821 8,042 (40%)

  20. Slide 20: ATRS – Five Year Revenue Mix Progression

    Slide 20: ATRS – Five Year Revenue Mix Progression

    ATRS – Five Year Revenue Mix Progression $20.6M $11.0M $13.2M $45.7M $27.5M $52.2M $40.3M $54.5M $41.7M 2018 Year-To-Date Revenue $26.9M

  21. Slide 21: ATRS – Building Momentum in 2H18

    Slide 21: ATRS – Building Momentum in 2H18

    ATRS – Building Momentum in 2H18 XYOSTED™ PDUFA goal date 9/29/18 - Potential Q418 launch Growth of Makena® auto injector in 2H18 Teva’s launch of the Generic EpiPen® Progress on development partnership with Pfizer for rescue pen Addition to pipeline of a strategic new proprietary drug/device R&D co

  22. Slide 22: H.C. Wainwright 20th Annual Global Investment Conference

    Slide 22: H.C. Wainwright 20th Annual Global Investment Conference

    NASDAQ: ATRS H.C. Wainwright 20th Annual Global Investment Conference September 6, 2018 Robert F. Apple President and Chief Executive Officer

  23. Slide 23: Appendix I: XYOSTED Phase Pharmacokinetic and Safety Results

    Slide 23: Appendix I: XYOSTED Phase Pharmacokinetic and Safety Results

    Appendix I XYOSTED™ Phase 3 Pharmacokinetic and Safety Results

  24. Slide 24: XYOSTED Phase Study Designs

    Slide 24: XYOSTED Phase Study Designs

    XYOSTED™ Phase 3 Study Designs QST-13-003 – 52-week single arm dose-blinded, concentration controlled multiple-dose, phase III study to evaluate efficacy and safety of XYOSTED™ administered subcutaneously once each week to testosterone-deficient males. The study included a screening phase, a treatme

  25. Slide 25: QST-13-003 PK Data Exceeded all Protocol-Required Outcomes

    Slide 25: QST-13-003 PK Data Exceeded all Protocol-Required Outcomes

    QST-13-003 PK Data Exceeded all Protocol-Required Outcomes1 Population/Analysis Cavg Lower limit of the 95% 2-sided C. I. C avg % in Range 300 – 1100 ng/dL n (%) Cmax <1500 ng/dL n (%) Cmax >1800 ng/dL n (%) Primary analysis* N=150 87.3% 139 (92.7%) 137 (91.3%)** 0% Completers N=137 94.8% 135 (98.5%

  26. Slide 26: XYOSTED Phase Safety Results

    Slide 26: XYOSTED Phase Safety Results

    XYOSTED™ Phase 3 Safety Results Previously Published Safety Results QST-13-003 - Adverse reactions (incidence ≥5%) reported were increased hematocrit, hypertension, increased prostate-specific antigen, Upper Respiratory Tract Infection, sinusitis, injection site bruising and headache. SAE’s reported

Source: SEC EDGAR · 8-K filed Sep 6, 2018

More decks from Antares Pharma Inc